This article is more than 5 years old. Information may no longer be current.
Rapid Response from Barcelona: New Data in HCV Treatment
Click Here to Manage Email Alerts
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. Rapid advancements in the field and interferon-free regimens approved for HCV, as well as several on the horizon, offer improved outcomes, shorter treatment durations, and unique adverse event profiles; therefore, clinicians must stay informed of the evolving data to counsel patients appropriately. Clinicians face challenges regarding how to make treatment choices among the numerous interferon-free regimens to improve treatment uptake and optimize outcomes in patients with HCV. This roundtable discussion among leading experts in HCV was recorded immediately following the 2016 EASL meeting in Barcelona, Spain, exploring some of the most recent findings and addressing the evidence-based clinical application of these data for HCV patients.
Click here to view this Education Lab Activity.
Learning Objectives:
Upon successful completion of this educational activity, participants should be better able to:
- Discuss the latest evidence for treatment duration in various patient populations with chronic HCV infection.
- Discuss the treatment of HCV in challenging patients such as those with rare or hard-to-treat HCV genotypes, advanced liver disease, chronic kidney disease, or who failed prior therapy.
- Evaluate the latest groundbreaking data for emerging oral regimens for the treatment of chronic HCV infection.
Overview
Author(s)/Faculty: Mark Sulkowski, MD; Graham R. Foster, FRCP, PhD; Ira M. Jacobson, MD; Stefan Zeuzem, MD
Source: Healio Gastroenterology Education Lab
Type: Video
Articles/Items: 3
Release Date: 5/5/2016
Expiration Date: 5/4/2017
Credit Type: CME
Number of Credits: 1
Cost: Free
Provider: Vindico Medical Education
CME Information
Sponsorship Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by an educational grant from AbbVie and Merck & Co. Inc.
Target Audience: The intended audience for the activity is gastroenterologists, hepatologists, gastroenterology/hepatology nurse practitioners and physician assistants, infectious disease physicians and other health care professionals involved in the treatment of patients with hepatitis C virus (HCV) infection.